Cardiac arrhythmia suppression trial. Jan 10, 2022 · Clinical trials sometimes surprise us.

Cardiac arrhythmia suppression trial Mar 21, 1991 · Background and methods: In the Cardiac Arrhythmia Suppression Trial, designed to test the hypothesis that suppression of ventricular ectopy after a myocardial infarction reduces the incidence of sudden death, patients in whom ventricular ectopy could be suppressed with encainide, flecainide, or moricizine were randomly assigned to receive Jan 3, 2018 · The Cardiac Arrhythmia Suppression Trial sought to evaluate the efficacy and safety of arrhythmia suppression therapy in patients with asymptomatic or mildly symptomatic ventricular arrhythmia after myocardial infarction. Secondary Endpoints: Tolerability of moricizine. Effect of Methods: The sample consisted of 348 patients in the Cardiac Arrhythmia Suppression Trial who had asymptomatic ventricular arrhythmias after myocardial infarction. A significant risk factor for mortality in post-MI patients is the presence of ventricular premature Aug 22, 1991 · To the Editor: The investigators of the Cardiac Arrhythmia Suppression Trial (CAST) (March 21 issue)1 found an excess of deaths due to arrhythmia and deaths due to shock after acute myocardial inf Aug 10, 1989 · The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic the … The occurrence of ventricular premature depolarizations in survivors of myocardial infarction is a risk factor for subsequent sudden death, but whether antiarrhythmic therapy reduces the risk is not known. The presence of ventricular ectopic activity in the post-myocardial infarction (post-MI) patient, especially when accompanied by left ventricular dysfunction, has been associated with a high incidence of sudden cardiac death. Treatment strategies designed solely to suppress these arrhythmias should no longer be followed. 1056/ Jan 1, 1995 · The Cardiac Arrhythmia Suppression Trial (CAST) was instituted in 1986 by the National Heart, Lung, and Blood Institute (NHLBI) after the completion of a 502-patient pilot study (CAPS). 1989 Aug 10;321(6):386-8. 2 3 In both trials, antiarrhythmic drugs effectively suppressed asymptomatic ventricular arrhythmias but The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic To the Editor: The final analysis of the data from the first Cardiac Arrhythmia Suppression Trial (CAST-I) (March 21, 1991, issue)1 did not address the problem of treatment with calcium-channel blo Jan 1, 1992 · Death due to arrhythmia Cardiac arrest due to arrhythmia requiring resuscitation. Background. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The main result of the CAST (Cardiac Arrhythmia Suppression Trial), shown in Figure 1,1 was completely unexpected: The suppression of ventricular ectopy with antiarrhythmic drugs (AADs) was associated with an increased incidence of lethal ventricular arrhythmias in patients with post–myocardial infarction (post-MI) at high risk of sudden See full list on acc. Instead, a preliminary finding from the CAST was that the encainide and fleca … The Multicenter PostInfarction Research Group study 1 and the Cardiac Arrhythmia Pilot Study 2 provided meticulous preparation for an interventional trial, but the outcome of the Cardiac The Cardiac Arrhythmia Suppression Trial (CAST) is a clinical trial that aimed to test whether the chronic suppression of certain types of heart rhythm abnormalities using certain medications would reduce mortality in patients who had experienced a heart attack. MI indicates myocardial infarction; VPDs, ventricular premature depolarizations. 1 2 3 The initial results of CAST I was published in 1989 and the CAST II results published in 1992. Jan 10, 2022 · Clinical trials sometimes surprise us. In Meyler's Side Effects of Drugs (Sixteenth Edition), 2016. N Engl J Med. Instead, a preliminary finding from the CAST was that the encainide and flecainide groups had a 3. The second CAST study (CAST-II Methods: The Cardiac Arrhythmia Suppression Trial was a multicenter, randomized, placebo-controlled trial designed to determine whether the suppression of ventricular premature depolarizations in postmyocardial infarction patients would improve survival. Psychosocial status was assessed with the Social Support Questionnaire-6, Social Readjustment Rating Scale, State-Trait Anxiety Inventory, Self-Rating Depression Scale, Jenkins The main result of the CAST (Cardiac Arrhythmia Suppression Trial), shown in Figure 1,1 was completely unexpected: The suppression of ventricular ectopy with antiarrhythmic drugs (AADs) was associated with an increased incidence of lethal ventricular arrhythmias in patients with post–myocardial infarction (post-MI) at high risk of sudden cardiac death (SCD). Drug/Procedures Used: Moricizine, 200mg tid titrated up to 900mg daily based on arrhythmia suppression (80% of ventricular premature depolarizations or 90% of runs of nonsustained ventricular tachycardia). doi: 10. Jan 1, 1995 · Study design to test the Cardiac Arrhythmia Suppression Trial (CAST) suppression hypothesis. Jan 16, 1990 · The Cardiac Arrhythmia Suppression Trial (CAST) was designed to test the hypothesis that suppression of ventricular premature complexes (VPCs) in survivors of acute myocardial infarction would reduce arrhythmic death risk. The trial was stopped early. Nov 24, 1993 · The suppression of asymptomatic or mildly symptomatic ventricular arrhythmias after myocardial infarction does not improve survival and can increase mortality. Jan 1, 1995 · 2 Cardiac Arrhythmia Suppression Trial (CAST) Investigators. 1989; 321:406-412. Crossref Medline Google Scholar; 3 The Cardiac Arrhythmia Suppression Trial-II Investigators. Moye, MD, PhD The Cardiac Arrhythmia Suppression Trial (CAST) was designed to test the hypothesis that suppres- sion of ventricular premature complexes (VPCs) in survivors of acute myocardial infarction would re- duce arrhythmic death risk. The Cardiac Arrhythmia Suppression Trial (CAST) was performed to test the hypothesis that premature ventricular complex Jan 16, 1990 · The Cardiac Arrhythmia Suppression Trial: Background, Interim Results and Implications Craig M. 1,2 CAST was a randomized placebo-controlled trial that evaluated the effects of three drugs — encainide, flecainide, and moricizine, which at the time of the trial were approved for use by the Food and Drug Administration (FDA) for the treatment of cardiac arrhythmias — on Jul 23, 1992 · The Cardiac Arrhythmia Suppression Trial (CAST) tested the hypothesis that the suppression of asymptomatic or mildly symptomatic ventricular premature depolarizations in survivors of myocardial Jan 16, 1990 · The Cardiac Arrhythmia Suppression Trial (CAST) was designed to test the hypothesis that suppression of ventricular premature complexes (VPCs) in survivors of acute myocardial infarction would reduce arrhythmic death risk. Mar 21, 1991 · In the Cardiac Arrhythmia Suppression Trial, designed to test the hypothesis that suppression of ventricular ectopy after a myocardial infarction reduces the incidence of sudden death, The Cardiac Arrhythmia Suppression Trial (CAST) was a double-blind, randomized, controlled study designed to test the hypothesis that suppression of premature ventricular complexes (PVC) with class I antiarrhythmic agents after a myocardial infarction (MI) would reduce mortality. The Cardiac Arrhythmia Suppression Trial (CAST) was designed to examine the hypothesis that suppressing asymptomatic or mildly symptomatic ventricular ectopic activity after myocardial infarction w Aug 10, 1989 · The cardiac arrhythmia suppression trial (CAST) The cardiac arrhythmia suppression trial (CAST) N Engl J Med. Three class I antiarrhythmic drugs were used: encainide, flecainide, or moricizine. Pratt, MD, and Lemuel A. org The Cardiac Arrhythmia Suppression Trial (CAST) was a study designed to test the hypothesis that suppression of ventricular premature complexes after a myocardial infarction would improve survival. 6-fold increase in arrhythmic death compared with their placebo group Jul 23, 1992 · Background: The Cardiac Arrhythmia Suppression Trial (CAST) tested the hypothesis that the suppression of asymptomatic or mildly symptomatic ventricular premature depolarizations in survivors of myocardial infarction would decrease the number of deaths from ventricular arrhythmias and improve overall survival. Definition of Cardiac Arrhythmia Suppression Trial in the Medical Dictionary by The Free Dictionary May 11, 2020 · This was attributable in part to CAST (the Cardiac Arrhythmia Suppression Trial), which demonstrated a significantly higher mortality in patients randomly assigned to encainide or flecainide in comparison with placebo in an effort to reduce ventricular ectopic beats after myocardial infarction. Cardiovascular. A classic surprise story is the Cardiac Arrhythmia Suppression Trial (CAST). In the wake of the preliminary and final reports of the Cardiac Arrhythmia Suppression Trial (CAST) [6, 7], which showed that there was an increased risk of death among patients who took encainide and flecainide after myocardial infarction, there have been many publications in which the implications of Jan 16, 1990 · The Cardiac Arrhythmia Suppression Trial (CAST) was instituted in 1986 by the National Heart, Lung, and Blood Institute after the completion of a 502-patient pilot study (CAPS) and the common practice of using antiarrhythmic drugs to suppress asymptomatic arrhythmias in patients after acute myocardial infarction has been curtailed. Encainide. . Dec 3, 2017 · The Cardiac Arrhythmia Suppression Trial (CAST I) randomized 1,500 post-MI patients with increased ventricular ectopy and depressed LV function to either encainide, flecainide or placebo. yskw myja bcw txnn rsjcqn yfwwtbi anfttz ilher krimrpc kgco